Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Discovery Labs Stories

2013-10-30 16:25:47

WARRINGTON, Pa., Oct. 30, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it is offering to sell shares of its common stock in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. Stifel and Piper Jaffray & Co. are acting as joint bookrunning managers for the offering, Lazard Capital Markets LLC is acting as co-lead...

2013-10-17 08:29:19

Important Neonatal Clinical Development Program Expected to Begin 4Q'13 WARRINGTON, Pa., Oct. 17, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate its AEROSURF(®) phase 2 clinical program. The FDA has confirmed receipt of...

2013-10-08 08:28:53

WARRINGTON, Pa., Oct. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent entitled "Capillary System With Fluidic Element." The Company holds a license to this patent (U.S. Patent Application. No. 12/285,312), which will provide additional...

2013-10-04 08:23:33

Commercial Introduction of SURFAXIN Planned for the Fourth Quarter of 2013 WARRINGTON, Pa., Oct. 4, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN(® )(lucinactant) Intratracheal Suspension which was approved for the prevention of...

2013-09-05 08:28:52

WARRINGTON, Pa., Sept. 5, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that Company management will be presenting at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, MA. The presentation is scheduled for Wednesday, September 11, 2013 at 11:30 a.m. ET. About Discovery Labs Discovery Laboratories, Inc. is a specialty...

2013-08-08 08:29:51

WARRINGTON, Pa., Aug. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reported financial results for the second quarter ended June 30, 2013 and also provided a business update. The Company will host a conference call this morning at 10:00 AM ET. Conference call details are below. Key updates include: -- SURFAXIN(®): On June 7, 2013, the Company submitted a...

2013-06-11 08:30:34

Follow-up SURFAXIN® (lucinactant) Data Analysis Presented at 2013 Pediatric Pharmacy Advocacy Group Annual Meeting WARRINGTON, Pa., June 11, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the presentation of the last in a series of pharmacoeconomic analyses indicating that a reduction in the rate of reintubation( )among preterm infants may potentially result in hospital cost-savings related to fewer reintubation-related diagnoses of...

2013-06-10 08:29:40

WARRINGTON, Pa., June 10, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that on June 7,( )2013 it submitted a response to the U.S. Food and Drug Administration's (FDA) recent correspondence relating to Discovery Labs' recently updated product specifications for SURFAXIN(®). Discovery Labs expects that the FDA may take up to four months to review the...

2013-05-15 12:33:53

WARRINGTON, Pa., May 15, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has completed its previously announced public offering to sell an aggregate of 9.5 million shares of its common stock under Discovery Labs' previously filed registration statement that was declared effective by the Securities and Exchange Commission on June 21, 2011. The offering remains subject to the underwriter's 30-day option to purchase up to an additional 1.425 million...

2013-05-10 08:25:14

WARRINGTON, Pa., May 10, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has priced an underwritten public offering of 9.5 million shares of its common stock, at a price to the public of $1.50 per share for gross proceeds of $14.25 million. Net proceeds, after underwriting discount and other estimated fees and expenses payable by the Company, are expected to be approximately $13.2 million. The offering is expected to close on or about May 15, 2013,...